Claims for Patent: 9,243,025

Summary for Patent: 9,243,025

Title:	Compounds and pharmaceutical compositions for the treatment of viral infections
Abstract:	Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Inventor(s):	Surleraux; Dominique (Wauthier-Braine, BE), Gosselin; Gilles (Montpellier, FR)
Assignee:	Idenix Pharmaceuticals, LLC (Cambridge, MA)
Application Number:	13/436,587
Patent Claims:	1. A compound of Formula I: ##STR00189## or a pharmaceutically acceptable salt, solvate, a tautomeric or polymorphic form thereof, wherein ##STR00190## A is R is a moiety derivable by removal of a hydrogen from a hydroxy group of an antiviral nucleoside or nucleoside analog; X is O or S; Q is OR.sup.4, SR.sup.4 or NR.sup.5R.sup.6; each E is independently CR.sup.7R.sup.8; n is 1 or 2; R.sup.1 and R.sup.2 are selected as follows: i) R.sup.1 and R.sup.2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl; or ii) R.sup.1 is hydrogen, alkyl or cycloalkyl, and R.sup.2 is (G).sub.mC(O)Q.sup.1, wherein Q.sup.1 is OR.sup.4, SR.sup.4 or NR.sup.5R.sup.6; each G is independently CR.sup.7R.sup.8; and each m is 1 or 2; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or alternatively when n is 1, R.sup.3 and R.sup.7 may together with the nitrogen and carbon atoms to which they are attached form a 4-7 membered heterocyclic ring, wherein the ring is unsubstituted or substituted by C(O)Q.sup.1; R.sup.4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; R.sup.5 and R.sup.6 are selected as follows: i) R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or ii) R.sup.5 and R.sup.6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring; and R.sup.7 and R.sup.8 are selected as follows: i) R.sup.7 and R.sup.8 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or ii) R.sup.7 and R.sup.8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring; and wherein if R.sup.2 is (G).sub.mC(O)Q.sup.1, G is CR.sup.7R.sup.8; m is 1, and one of R.sup.7 or R.sup.8 is hydrogen, the other of R.sup.7 and R.sup.8 is not methyl; and wherein ##STR00191## one of R.sup.1 or R.sup.2 is hydrogen. 2. The compound of claim 1 of Formula I, wherein R.sup.7 and R.sup.8 are selected as follows: i) R.sup.7 and R.sup.8 are each independently hydrogen, C.sub.2-C.sub.10 alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or ii) R.sup.7 and R.sup.8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring. 3. The compound of claim 1, wherein one of R.sup.7 or R.sup.8 is C.sub.2-C.sub.6 alkyl. 4. The compound of claim 1, wherein R.sup.1 and R.sup.3 are each hydrogen; R.sup.2 is (G).sub.mC(O)Q.sup.1; and m is 1. 5. The compound of claim 1, wherein R.sup.1 and R.sup.3 are each hydrogen; R.sup.2 is (G).sub.mC(O)Q.sup.1; and m is 2. 6. The compound of claim 1, wherein Q and Q.sup.1 are each OR.sup.4 and each R.sup.4 is alkyl. 7. The compound of claim 1, wherein R.sup.1 and R.sup.3 are each hydrogen; R.sup.2 is (G).sub.mC(O)Q.sup.1; m is 1; Q.sup.1 is OR.sup.4; and R.sup.4 is alkyl. 8. The compound of claim 1, wherein R.sup.1 and R.sup.3 are each hydrogen; R.sup.2 is (G).sub.mC(O)Q.sup.1; m is 1; Q.sup.1 is OR.sup.4; and R.sup.4 is alkyl; each R.sup.7 is hydrogen; and each R.sup.8 is alkyl, alkylaryl or alkylheteroaryl. 9. The compound of claim 1, wherein; n is 1; R.sup.3 and R.sup.7 together with the nitrogen and carbon atoms to which they are attached form a 5 membered heterocyclic ring substituted by C(O)Q.sup.1; each Q.sup.1 is OR.sup.4; each R.sup.4 is alkyl; and each R.sup.8 is alkyl, alkylaryl or alkylheteroaryl. 10. The compound of claim 1, wherein X is O. 11. A compound of Formula II: ##STR00192## or a pharmaceutically acceptable salt, a tautomeric or polymorphic form thereof, wherein; Base is a substituted or unsubstituted purine or pyrimidine; W is alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl, each of which is not substituted; X is O or S; Y is hydrogen or OR.sup.9; Z is hydrogen, OR.sup.10, Se, NR.sup.5R.sup.6, F, Cl, Br or I; Q is OR.sup.4, SR.sup.4 or NR.sup.5R.sup.6; each E is independently CR.sup.7R.sup.8; each n is 1 or 2; R.sup.1 and R.sup.2 are selected as follows: i) R.sup.1 and R.sup.2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, each of which is not substituted; ii) R.sup.1 and R.sup.2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q.sup.1; or iii) R.sup.1 is hydrogen, alkyl or cycloalkyl, and R.sup.2 is (G).sub.mC(O)Q.sup.1, wherein Q.sup.1 is OR.sup.4, SR.sup.4 or NR.sup.5R.sup.6; each G is independently CR.sup.7R.sup.8; and each m is 1 or 2; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl, each of which is not substituted; or alternatively when n is 1, R.sup.3 and R.sup.7 may together with the nitrogen and carbon atoms to which they are attached form a 4-7 membered heterocyclic ring, wherein the ring is unsubstituted or substituted by C(O)Q.sup.1; R.sup.4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl, each of which is not substituted; R.sup.5 and R.sup.6 are selected as follows: i) R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or ii) R.sup.5 and R.sup.6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, each of which is not substituted; R.sup.7 and R.sup.8 are selected as follows: i) R.sup.7 and R.sup.8 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy, and the other groups are not substituted; or ii) R.sup.7 and R.sup.8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring which is not substituted; R.sup.9 and R.sup.10 are selected as follows: i) R.sup.9 and R.sup.10 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl, each of which is not substituted; or ii) R.sup.9 and R.sup.10 together with C(O) and the oxygen or sulfur atoms on which they are substituted form a 5 membered ring. 12. The compound of claim 11, wherein if R.sup.2 is (G).sub.mC(O)Q.sup.1, G is CR.sup.7R.sup.8, m is 1, and one of R.sup.7 or R.sup.8 is hydrogen; the other of R.sup.7 and R.sup.8 is not methyl. 13. The compound of claim 11, wherein Y is OR.sup.9 and Z is OR.sup.10 or F. 14. The compound of claim 11, wherein W is alkyl, alkenyl or alkynyl. 15. The compound of claim 14, wherein W is alkyl. 16. The compound of claim 11, wherein W is ethynyl; Y is OR.sup.9; Z is F; and R.sup.9 is hydrogen. 17. The compound of claim 11, wherein W is methyl; Y is OR.sup.9; Z is F; and R.sup.9 is hydrogen. 18. The compound of claim 11, wherein W is methyl; Y is OR.sup.9; Z is OR.sup.10; and R.sup.9 and R.sup.10 are each hydrogen. 19. The compound of claim 11, wherein R.sup.1 and R.sup.3 are each hydrogen; and R.sup.2 is (G).sub.mC(O)Q.sup.1. 20. The compound of claim 11, wherein Q and Q.sup.1 are each OR.sup.4. 21. The compound of claim 11, wherein Q and Q.sup.1 are each SR.sup.4. 22. The compound of claim 11, wherein each R.sup.4 is alkyl. 23. The compound of claim 11, wherein Q and Q.sup.1 are each NR.sup.5R.sup.6. 24. The compound of claim 11, wherein X is O. 25. The compound of claim 11, wherein m is 1. 26. The compound of claim 11, wherein n is 1. 27. The compound of claim 11, wherein m is 2. 28. The compound of claim 11, wherein n is 2. 29. The compound of claim 11, wherein each R.sup.7 is hydrogen; and each R.sup.8 is independently alkyl, aryl, aralkyl or alkylheteroaryl. 30. The compound of claim 29, wherein each R.sup.8 is C.sub.2-C.sub.10 alkyl. 31. The compound of claim 29, wherein each R.sup.8 is C.sub.2-C.sub.6 alkyl. 32. The compound of claim 29, wherein each R.sup.8 is C.sub.3-C.sub.6 alkyl. 33. The compound of claim 29, wherein each R.sup.8 is isobutyl. 34. The compound of claim 29, wherein each R.sup.8 is sec-butyl. 35. The compound of claim 29, wherein each R.sup.8 is phenyl. 36. The compound of claim 29, wherein each R.sup.8 is benzyl. 37. The compound of claim 29, wherein each R.sup.8 is 1-H-indol-3-ylmethyl. 38. The compound of claim 11, wherein each of R.sup.7 and R.sup.8 is alkyl. 39. The compound of claim 11, wherein R.sup.7 and R.sup.8 together with the carbon atom to which they are attached form a 5 membered cycloalkyl ring. 40. The compound of claim 1, wherein, when E, Q, Q.sup.1, R.sup.1, R.sup.2, R.sup.5, R.sup.6, n and m form at least one amino acid group, the amino acid is in the L-configuration. 41. The compound of claim 11, wherein Base is adenine, cytosine, guanine, hypoxanthine, thymine or uridine. 42. The compound of claim 41, wherein Base is cytosine. 43. The compound of claim 41, wherein Base is guanine. 44. The compound of claim 41, wherein Base is uridine. 45. The compound of claim 11, wherein Base is selected from one of formulae (i) to (xxvi): ##STR00193## ##STR00194## ##STR00195## ##STR00196## ##STR00197## wherein each R.sup.L is independently hydrogen, alkyl, cycloalkyl, acyl, carbamyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, alkyl sulfonyl, aryl sulfonyl, arylalkyl sulfonyl, a lipid, a phospholipid, an amino acid or a carbohydrate, each of which is not substituted; and each R.sup.M and R.sup.N is independently hydrogen or unsubstituted alkyl; or R.sup.L and R.sup.M together with the N atom to which they are attached form unsubstituted heterocyclyl. 46. The compound of claim 45, wherein R.sup.L is hydrogen, alkyl or cycloalkyl. 47. The compound of claim 45, wherein R.sup.L is cyclopropyl or cyclopentyl. 48. The compound of claim 45, wherein R.sup.L is methyl, ethyl, propyl, or isopropyl. 49. The compound of claim 45, wherein R.sup.M is hydrogen. 50. The compound of claim 45, wherein R.sup.M is methyl. 51. The compound of claim 45, wherein Base is selected from ##STR00198## wherein R.sup.L and R.sup.M together with the N atom to which they are attached from pyrrolidinyl or morpholinyl. 52. The compound of claim 1, wherein R is a moiety derivable by removal of a hydrogen from a hydroxy group of selected from ribavirin, viramidine, valopicitabine, PSI-6130, PSI-6206, PSI-35938 and R1479. 53. A compound of claim 1, or a pharmaceutically acceptable salt, a tautomeric or polymorphic form thereof, of the formula: ##STR00199## ##STR00200## ##STR00201## ##STR00202## ##STR00203## ##STR00204## ##STR00205## ##STR00206## ##STR00207## ##STR00208## ##STR00209## ##STR00210## 54. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent. 55. The pharmaceutical composition of claim 54, wherein the composition is an oral formulation. 56. A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound or composition of claim 1. 57. The method of claim 56, wherein the host is a human. 58. The method of claim 56, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host. 59. The method of claim 56, wherein said compound or composition is administered in combination or alternation with a second anti-viral agent selected from an interferon, a ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine derivative, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, a cerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, or a ribozyme. 60. The method of claim 59, wherein the second agent is pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta or interferon .gamma.-1b.

Details for Patent 9,243,025

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2031-03-31
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2031-03-31
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2031-03-31
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2031-03-31